Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
10.14
-0.22 (-2.12%)
Jan 17, 2025, 4:00 PM EST - Market closed
Replimune Group Employees
Replimune Group had 331 employees as of March 31, 2024. The number of employees increased by 47 or 16.55% compared to the previous year.
Employees
331
Change (1Y)
47
Growth (1Y)
16.55%
Revenue / Employee
n/a
Profits / Employee
-$643,571
Market Cap
780.33M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
REPL News
- 10 days ago - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch - Seeking Alpha
- 2 months ago - Replimune Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 2 months ago - Replimune Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway - GlobeNewsWire
- 2 months ago - Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) - GlobeNewsWire
- 2 months ago - Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire